Sarah Haecker Meeks, an expert in gene therapy, is to lead business development at Synpromics Ltd, the Edinburgh, UK-based synthetic biology company. Dr Haecker Meeks will be based in the US at Synpromics Inc, a recently-established subsidiary.
Dr Haecker Meeks was previously chief scientific officer at Adjuvant Partners LLC where she gave business advice to companies developing cell and gene therapy. She is a co-founder of Cardiogen Sciences Inc. (now part of Audentes Therapeutics) and was head of the gene therapy section at the Alliance for Regenerative Medicine. She earned a doctorate in molecular biology and bioethics from the University of Minnesota and a bachelor of science degree in biochemistry from the University of Wisconsin, US.
Synpromics announced the appointment on 17 January 2018.
Copyright 2018 Evernow Publishing Ltd